Navigation Links
ThromboGenics Presents Positive Pooled Results from the MIVI-TRUST Phase III Program, Confirming Microplasmin's Potential to Transform the Treatment of Retinal Disorders
Date:9/6/2010

ead to macular hole, where the traction from the vitreomacular adhesion actually pulls off a piece of the macula (the part of the retina responsible for central vision). If not treated with major eye surgery called a vitrectomy, which involves using suction to remove the vitreous from the eye, macular hole can lead to irreversible, central blindness. While vitrectomy is generally effective in closing macular holes, it is an invasive procedure and a proportion of patients experience side-effects. These include alteration of vision, bleeding, retinal detachment and development of glaucoma and cataracts. Therefore, a nonsurgical treatment option for such patients could be an important breakthrough in the way macular hole patients are treated.

The MIVI-TRUST Program

The microplasmin Phase III program, referred to as MIVI-TRUST (Microplasmin for IntraVitreous Injection-Traction Release without Surgical Treatment), consists of two multi-center, randomized, placebo controlled, double-masked trials. These trials are designed to evaluate a single dose of 125μg microplasmin versus placebo in the intravitreal treatment of patients with symptomatic focal vitreomacular adhesion (VMA). The primary endpoint of both trials is the non-surgical resolution of focal vitreomacular adhesion one month after a single injection of microplasmin. This endpoint is assessed using optical coherence tomography (OCT). The MIVI-TRUST program is the largest interventional clinical program ever performed to specifically evaluate the vitreoretinal interface in patients with retinal disorders. In total, over 650 patients were enrolled in these trials, which were held across 90 centers in 7 countries.

About ThromboGenics

ThromboGenics is a biopharmaceutical company focused on the discovery and development of innovative medicines for the treatment of eye disease, vascular disease and cancer. The Company's lead product microplasmin has completed two P
'/>"/>

SOURCE ThromboGenics NV
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine technology :

1. ThromboGenics Completes Patient Enrolment in the Phase IIb Trial of Microplasmin in Vitrectomy (MIVI III)
2. ThromboGenics Announces Promising Results of MITI IV Phase II Trial in the Treatment of Acute Stroke with Microplasmin
3. ThromboGenics Begins Phase III Program With Microplasmin for the Non-surgical Treatment of Back of the Eye Disease
4. ThromboGenics and BioInvent Receive Technology Transfer Success Fee From Roche for the Novel Anti-Cancer Antibody, TB-403 (Anti-PIGF)
5. ThromboGenics Completes Patient Enrolment for Phase II Trial of Microplasmin for the Treatment of Diabetic Macular Edema (MIVI II DME)
6. ThromboGenics Microplasmin Phase III Program Progressing According to Schedule
7. ThromboGenics and BioInvent Start Recruitment of Second 100 Patient Cohort in Phase II DVT Prophylaxis Study With TB-402
8. ThromboGenics Completes Patient Enrolment in US Phase III Trial of Microplasmin for the Non-Surgical Treatment of Eye Disease
9. ThromboGenics and BioInvent Complete Patient Recruitment of Phase II DVT Prophylaxis Study With Anti-Factor VIII (TB-402)
10. ThromboGenics Completes Patient Enrolment of Second Phase III Trial of Microplasmin for the Non-Surgical Treatment of Eye Disease
11. ThromboGenics Announces Start of Phase II Trial of Microplasmin for the Treatment of Age-Related Macular Degeneration (AMD)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... September 2, 2014 According ... Market Research "Latin America Home Healthcare Market (By ... Healthcare Devices, Mobility Assist Devices and Medical Supplies; ... Infusion Therapy and Unskilled Home Healthcare Services) - ... 2014 - 2020" the Latin American Home Healthcare ...
(Date:9/2/2014)... Calif. , Sept. 2, 2014   Santa ... now offering a special promotion for Invisalign. Invisalign is ... brackets and wires. It is often the orthodontic treatment ... the convenience and aesthetics of it. For a limited ... is a significant savings from the usual cost. This ...
(Date:9/2/2014)... España, September 2, 2014 ... fibrilación atrial muestran agentes antitrombóticos no utilizados óptimamente ... -- Las presentaciones de GARFIELD-AF en el ... tratamiento y los resultados de pacientes en riesgo ... --    Los datos de casi ...
Breaking Medicine Technology:Home Healthcare Market in Latin America Expected to Reach USD 17.5 Billion in 2020: Transparency Market Research 2Home Healthcare Market in Latin America Expected to Reach USD 17.5 Billion in 2020: Transparency Market Research 3Home Healthcare Market in Latin America Expected to Reach USD 17.5 Billion in 2020: Transparency Market Research 4Home Healthcare Market in Latin America Expected to Reach USD 17.5 Billion in 2020: Transparency Market Research 5Home Healthcare Market in Latin America Expected to Reach USD 17.5 Billion in 2020: Transparency Market Research 6Santa Clara Cosmetic Dentist, Dr. Alan Frame, is Now Offering a Special on Invisalign 2Los datos sobre fibrilación atrial muestran agentes antitrombóticos no usados óptimamente para prevenir la apoplejía 2Los datos sobre fibrilación atrial muestran agentes antitrombóticos no usados óptimamente para prevenir la apoplejía 3Los datos sobre fibrilación atrial muestran agentes antitrombóticos no usados óptimamente para prevenir la apoplejía 4Los datos sobre fibrilación atrial muestran agentes antitrombóticos no usados óptimamente para prevenir la apoplejía 5Los datos sobre fibrilación atrial muestran agentes antitrombóticos no usados óptimamente para prevenir la apoplejía 6Los datos sobre fibrilación atrial muestran agentes antitrombóticos no usados óptimamente para prevenir la apoplejía 7Los datos sobre fibrilación atrial muestran agentes antitrombóticos no usados óptimamente para prevenir la apoplejía 8Los datos sobre fibrilación atrial muestran agentes antitrombóticos no usados óptimamente para prevenir la apoplejía 9Los datos sobre fibrilación atrial muestran agentes antitrombóticos no usados óptimamente para prevenir la apoplejía 10Los datos sobre fibrilación atrial muestran agentes antitrombóticos no usados óptimamente para prevenir la apoplejía 11
... , WASHINGTON, Dec. 14 ... counsel on global and domestic communications and issues management, ... PositiveID Corporation (Nasdaq: PSID ) to serve as ... will conduct media relations for PositiveID,s corporate communications and ...
... , NEW HAVEN, Conn., ,Dec. 14 /PRNewswire-FirstCall/ ... today announced that it had received a complete response ... related to its New Drug Application ("NDA") for Onrigin(TM) ... indicates that the FDA cannot approve the Company,s NDA ...
Cached Medicine Technology:Gibraltar Associates Named Agency of Record for Health Information and Diagnostic Provider PositiveID Corporation 2Vion Pharmaceuticals Receives Complete Response Letter for Onrigin(TM) From The U.S. Food And Drug Administration 2Vion Pharmaceuticals Receives Complete Response Letter for Onrigin(TM) From The U.S. Food And Drug Administration 3
(Date:9/2/2014)... A New York City based company is ... yet revolutionary, product that will have far-reaching, ... care costs for Americans. , REMIND-A-CAP™ is ... control in the user's hands. It's a simple device ... date of intake by simply turning a knob. No ...
(Date:9/2/2014)... Welcome to Arthritis Awareness Month ... Canadians living with the disease, The Arthritis Society is ... series featuring well-known Canadians from different walks of life ... Lloyd Robertson , veteran news anchor , ... ,      Amy Cotton , two-time Olympic wrestler ...
(Date:9/2/2014)... A little white pill may help scientists learn why ... their peers, even if their lungs are relatively healthy. ... marketed as Revatio to treat pulmonary hypertension and Viagra ... of over-the-counter antioxidants will help them identify the root ... for these patients. , "We want to understand ...
(Date:9/2/2014)... Cardiology Congress in Barcelona shows that having a family ... motivate people to follow healthy lifestyles. , Researchers ... online tool that engages people presenting their personal CVD ... the hypothesis that those who have a family history ... and blood pressure checks and be motivated to adopt ...
(Date:9/2/2014)... be a new salve to dominate medicine cabinets of the ... Salamanders may not be the cuddliest of animals, but they ... damaged body parts. Now, a new report published in the ... , identifies a small protein (called a "peptide") from the ... the secret of this amazing wound healing trick in humans. ...
Breaking Medicine News(10 mins):Health News:REMIND-A-CAP™ , A New York City Based Company Invents Groundbreaking Prescription Cap to Curb Non-Adherence 2Health News:‘Voices of Arthritis’ Launches Awareness Month 2Health News:‘Voices of Arthritis’ Launches Awareness Month 3Health News:Drug that improves blood flow may help find cause of exercise intolerance in cystic fibrosis 2Health News:Drug that improves blood flow may help find cause of exercise intolerance in cystic fibrosis 3Health News:Drug that improves blood flow may help find cause of exercise intolerance in cystic fibrosis 4Health News:Family history of cardiovascular disease is not enough to motivate people to follow healthy lifestyle 2Health News:Salamander skin peptide promotes quick and effective wound healing in mice 2
... finds chlorthalidone most likely to prevent heart failure, ... Tried-and-true diuretics maintain their status as the best ... high blood pressure, new research concludes. , The ... a calcium channel blocker, an ACE inhibitor and ...
... Nov. 18 The U.S. Agency for International Development (USAID) ... up with Chicago Cubs Charities Nov. 17 to donate $100,000 ... Basic School and Education Center for Integrated Health (CESI). , ... and...Loyola and Creighton (universities) to help children and their families ...
... Release Statewide Data , HARRISBURG, Pa., Nov. 18 Pennsylvania is ... and adults living with autism, according to the Pennsylvania Autism Census ... , "With the release of this report, Pennsylvania becomes the first ... to meet the needs of the rapidly growing population of children ...
... The National Patient Safety Foundation (NPSF) today issued the following position ... The National Patient Safety Foundation recognizes vaccine-preventable, ... and supports mandatory, influenza vaccination of ... patients, health care workers, and the community. NPSF appreciates, ...
... Nov. 18 Hospice workers have seen patients hang onto ... from the Frances Payne Bolton School of Nursing and the ... will study what drives the dying to resolve unfinished business. ... Prince-Paul from nursing and Julie Exline from arts and sciences ...
... at Mount Sinai School of Medicine set out to ... years: How do dietary restrictionand the reverse, overconsumptionproduce protective ... in a two-part study led by Charles Mobbs, PhD, ... at Mount Sinai School of Medicine, published in the ...
Cached Medicine News:Health News:Diuretics Still Best Treatment for High Blood Pressure 2Health News:USAID, Cubs Charities Make a Grand Slam for Health and Basic Education 2Health News:PA Governor Rendell: New Report Shows Demand for Autism Services will Continue to Rise 2Health News:National Patient Safety Foundation Supports Mandatory Flu Vaccinations for Healthcare Workers 2Health News:National Patient Safety Foundation Supports Mandatory Flu Vaccinations for Healthcare Workers 3Health News:Research Collaboration Focuses on Unfinished Business at the End of Life 2Health News:Scientists find molecular trigger that helps prevent aging and disease 2Health News:Scientists find molecular trigger that helps prevent aging and disease 3
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: